VERA THERAPEUTICS INC. - CLASS A COMMON STOCK

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 7 2024 16:30:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer

01 7 2024 08:00:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics Appoints Christy J. Oliger to Board of Directors

11 6 2024 16:01:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

07 6 2024 16:05:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 6 2024 16:05:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)

28 5 2024 08:00:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress

25 5 2024 09:40:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

09 5 2024 08:00:01 提供 Nasdaq GlobeNewswire

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 5 2024 16:38:19 提供 Nasdaq GlobeNewswire

Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress

02 4 2024 08:00:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

20 3 2024 07:30:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference

28 2 2024 16:20:12 提供 Nasdaq GlobeNewswire

Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

02 2 2024 08:00:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock

01 2 2024 16:05:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock

29 1 2024 23:50:31 提供 Nasdaq GlobeNewswire

Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

29 1 2024 06:15:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy

25 1 2024 06:30:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer

08 1 2024 08:01:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics to Host In-Person R&D Day in New York to Present Week 72 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN on January 25, 2024

08 1 2024 08:00:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

27 12 2023 08:00:00 提供 Nasdaq GlobeNewswire